Restricted accessResearch articleFirst published online 2025-10
Impact of Contrast-Associated Acute Kidney Injury on One-Year Outcomes in Very Elderly STEMI Patients: Insights From a Multicenter Registry in Northern Italy
Data about contrast-associated acute kidney injury (CA-AKI) in oldest old (age ≥85 years) ST-elevation myocardial infarction (STEMI) patients are scarce. We evaluated the incidence and the 1-year prognostic impact of CA-AKI in this population. Patients were included in a multicenter real-world registry, and CA-AKI was defined according to KDIGO (Kidney Disease Improving Global Outcomes) criteria. Major adverse cardiac and cerebrovascular events (MACCEs) were defined as the composite of all-cause death, stroke, unplanned coronary revascularization, and heart failure hospitalization. The primary outcome was the incidence and impact of CA-AKI on MACCEs at 1 year follow-up. Out of 461 STEMI patients (mean age 88.6 ± 2.9 years), 102 (22.1%) patients developed CA-AKI. Chronic kidney disease was the strongest predictor of CA-AKI (odds ratio [OR]: 4.52, 95% CI: 2.81–7.30, P < .01). The CA-AKI cohort showed a higher risk of MACCEs (adjusted HR: 1.75, 95% CI: 1.13–2.71, P = .01), driven mainly by all-cause death (adjusted hazard ratio [HR]: 2.39, 95% CI: 1.41–4.07, P = .01) and followed by heart failure hospitalization (adjusted HR: 2.01, 95% CI: 1.08–3.76, P = .01). Among oldest old STEMI, CA-AKI was frequent and associated with a higher incidence of MACCEs at 1-year follow-up.
AndreisABudanoCLevisM, et al.Contrast-induced kidney injury: how does it affect long-term cardiac mortality?J Cardiovasc Med.2017;18(11):908-915.
2.
McCulloughPA. Contrast-Induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419-1428.
3.
MehranRDangasGDWeisbordSD. Contrast-associated acute kidney injury. N Engl J Med. 2019;380(22):2146-2155.
4.
StaculFvan der MolenAJReimerP, et al.Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines. Eur Radiol. 2011;21(12):2527-2541.
5.
WarrenJMehranRBaberU, et al.Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: insights from the harmonizing outcomes with revascularization and Stents in acute myocardial infarction (HORIZONS-AMI) and acute catheterization and urgent intervention triage strategy (ACUITY) trials. Am Heart J. 2016;171:40-47.
6.
Van PeetPGDrewesYMDe CraenAJM, et al.Prognostic value of cardiovascular disease status: the Leiden 85-plus study. Age. 2013;35(4):1433.
7.
CollertonJBarrassKBondJ, et al.The Newcastle 85+ study: biological, clinical and psychosocial factors associated with healthy ageing: study protocol. BMC Geriatr. 2007;7:14.
8.
De BoerSPMWesterhoutCMSimesRJ, et al.Mortality and morbidity reduction by primary percutaneous coronary intervention is independent of the patient’s age. JACC Cardiovasc Interv. 2010;3:324-331.
9.
AlexanderKPNewbyLKArmstrongPW, et al.Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2570-2589.
10.
GurwitzJHGoldbergRJ. Age-based exclusions from cardiovascular clinical trials: implications for elderly individuals (and for all of us): comment on “the persistent exclusion of older patients from ongoing clinical trials regarding heart failure”. Arch Intern Med. 2011;171:557-558.
11.
WindeckerSKolhPAlfonsoF, et al.ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS)developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619.
12.
NeumannFJSousa-UvaMAhlssonA, et al.2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165.
13.
ThygesenKAlpertJSJaffeAS, et al.Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):e618–e651.
14.
KellumJALameireNAspelinP, et al.Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138.
15.
GiacoppoDMadhavanMVBaberU, et al.Impact of contrast-induced acute kidney injury after percutaneous coronary intervention on short- and long-term outcomes. Circ Cardiovasc Interv. 2015;8(8):e002475.
16.
RihalCSTextorSCGrillDE, et al.Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-2264.
17.
StegPGGoldbergRJGoreJM, et al.Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002;90(4):358-363.
18.
YeJLiuCDengZ, et al.Original research: risk factors associated with contrast-associated acute kidney injury in ST-segment elevation myocardial infarction patients: a systematic review and meta-analysis. BMJ Open. 2023;13(6):70561.
19.
QueirozREBDe OliveiraLSNDe AlbuquerqueCA, et al.Acute kidney injury risk in patients with ST-segment elevation myocardial infarction at presentation to the ED. Am J Emerg Med. 2012;30(9):1921-1927.
20.
CocaSG. Acute kidney injury in elderly persons. Am J Kidney Dis. 2010;56(1):122-131.
21.
PavasiniRTebaldiMBuganiG, et al.Clinical medicine contrast associated acute kidney injury and mortality in older adults with acute coronary Syndrome: a pooled analysis of the FRASER and HULK studies. J Clin Med. 2021;10:2151.
22.
CosentinoNRestaMLSomaschiniA, et al.Acute kidney injury and in-hospital mortality in patients with ST-elevation myocardial infarction of different age groups. Int J Cardiol. 2021;344:8-12.
23.
SantopintoJJJohnsonJGurfinkelEP, et al.Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart. 2003;89(9):1003-1008.
24.
ShlipakMGHeidenreichPANoguchiH, et al.Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137(7):555-562.
25.
AnavekarNSMcMurrayJJVVelazquezEJ, et al.Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285-1295.
26.
MehtaRLKellumJAShahSv., et al.Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31–R31.
27.
HarringtonJJonesWSUdellJA, et al.Acute decompensated heart failure in the setting of acute coronary Syndrome. JACC Heart Fail. 2022;10(6):404-414.
28.
DammanKNavisGSmildeTDJ, et al.Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007;9(9):872-878.
29.
MarenziGAssanelliECampodonicoJ, et al.Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med. 2010;38(2):438-444.
30.
WangCPeiYYMaYH, et al.Risk factors for acute kidney injury in patients with acute myocardial infarction. Chin Med J. 2019;132(14):1660-1665.
31.
WeisbordSDMorMKResnickAL, et al.Prevention, incidence, and outcomes of contrast-induced acute kidney injury. Arch Intern Med. 2008;168(12):1325-1332.
32.
DodsonJAHajdukACurtisJ, et al.Acute kidney injury among older patients undergoing coronary angiography for acute myocardial infarction: the SILVER-AMI study. Am J Med. 2019;132(12):e817–e826.
33.
NarulaAMehranRWeiszG, et al.Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J. 2014;35(23):1533-1540.
34.
HeerspinkHJLStefánssonBv.Correa-RotterR, et al.Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.
35.
PackerMAnkerSDButlerJ, et al.Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424.
36.
JhundPSSolomonSDDochertyKF, et al.Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298-309.
37.
BeltramiMMilliMDeiLL, et al.The treatment of heart failure in patients with chronic kidney disease: doubts and new developments from the last ESC guidelines. J Clin Med. 2022;11(8):2243.
38.
ZannadFFerreiraJPPocockSJ, et al.Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced. Circulation. 2021;143(4):310-321.
39.
HeerspinkHJLOshimaMZhangH, et al.Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial. Am J Kidney Dis. 2022;79(2):244-256.
40.
HillegeHLvan GilstWHvan VeldhuisenDJ, et al.Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J. 2003;24(5):412-420.
41.
MoriciNde ServiSTosoA, et al.Renal function estimation and one-year mortality in elderly patients with non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2014;174(1):127-128.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
